Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
The British journal of dermatology（2022）
Abstract
This integrated safety analysis in patients with severe AA is consistent with the overall safety profile of baricitinib. Some differences with atopic dermatitis were noted that may be attributable to the disease characteristics of AA.
MoreTranslated text
Key words
severe alopecia areata,baricitinib,clinical trials
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined